Correspondence 0001640334-24-000412 from Lexaria Bioscience Corp. (LEXX, LEXXW) (CIK 0001348362) (LEXX)
Lexaria Bioscience Corp. (LEXX, LEXXW) (CIK 0001348362)
Date: March 18, 2024 · CIK: 0001348362 · Accession: 0001640334-24-000412
AI Filing Summary & Sentiment
File numbers found in text: 333-277863
Letter
lxrp_corresp.htm
March 18, 2024
VIA EDGAR AND FACSIMILE
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Tamika Sheppard
Re:
Lexaria Bioscience Corp. (the “Company”)
Registration Statement on Form S-1
File No. 333-277863
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30PM EDT on Wednesday, March 20, 2024, or as soon thereafter as is practicable.
The Company hereby acknowledges that:
●
should the United States Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
●
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
●
the Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions, please call Avital Perlman at 212-930-9700.
Very truly yours,
LEXARIA BIOSCIENCE CORP.
Show Raw Text
CORRESP
1
filename1.htm
lxrp_corresp.htm
March 18, 2024
VIA EDGAR AND FACSIMILE
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Tamika Sheppard
Re:
Lexaria Bioscience Corp. (the “Company”)
Registration Statement on Form S-1
File No. 333-277863
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30PM EDT on Wednesday, March 20, 2024, or as soon thereafter as is practicable.
The Company hereby acknowledges that:
●
should the United States Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
●
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
●
the Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions, please call Avital Perlman at 212-930-9700.
Very truly yours,
LEXARIA BIOSCIENCE CORP.
By:
/s/ Christopher Bunka
Name:
Christopher Bunka
Title:
Chief Executive Officer